Joseph M. Unger|Dawn L. Hershman|Raymond U. Osarogiagbon|Anirudh Gothwal|Seerat Anand|Arvind Dasari|Michael J. Overman|Jonathan M. Loree|Kanwal Raghav
Representativeness of Black Patients in Cancer Clinical Trials Sponsored by the National Cancer Institute Compared With Pharmaceutical Companies
Fred Hutch Cancer Center|Columbia University|Baylor University|The University of Texas MD Anderson Cancer Center|The University of Texas MD Anderson Cancer Center|The University of Texas MD Anderson Cancer Center|The University of Texas MD Anderson Cancer Center
many clinical trials supporting new drug applications underrepresent minority patients trials conducted national cancer institutes national clinical trials network nctn greater outreach community sites potentially allowing better representation compared representation black patients pharmaceutical companysponsored cancer clinical trials nctn trials us cancer populationwe established large cohort study publications representing results trials supported new us food drug administration drug approvals 2008 2018 nctn trial data swog cancer research network us cancer population rates estimated using surveillance epidemiology end results survey data compared proportion black patients enrollment year cancer type overall tests proportions used statistical tests 2sideda total 358 trials pharmaceutical companysponsored trials 85 swog trials 273 comprised 93 825 patients pharmaceutical companysponsored trials 46 313 swog trials 47 512 15 cancer types analyzed overall proportion black patients 29 pharmaceutical companysponsored trials 90 swog trials 121 us cancer population p 001 pairwise comparison findings generally consistent across individual cancer typesthe poor representation black patients pharmaceutical companysponsored trials supporting new drug applications could result use new drugs little data efficacy side effects key population moreover pharmaceutical companysponsored trials test newest available therapies limited access trials represents disparity access potential breakthrough therapies